Ocedurenone
Small moleculeexperimental
Clinical trial activity
11 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
5
Phase 3
2
Phase 4
1
Earliest trial started Jun 1, 2014 (NCT02228733)
Timeline
Indications
Approved for
Mechanism of action
- Mineralocorticoid receptorANTAGONIST
NR3C2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
N#Cc1ccc(N2N=C3c4ccc(C(=O)N5CCC(O)CC5)nc4CC[C@@H]3[C@@H]2C2CCCC2)cc1Cl- Mol. weight
- 504.03 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314961 ↗
Also known as
- kbp-5074
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06058585 | Phase 3 | May 15, 2024 | University of New South Wales |
| NCT04968184 | Phase 3 | Nov 10, 2021 | KBP Biosciences |
| NCT04634812 | Phase 1 | Dec 3, 2020 | Covance, KBP Biosciences |
| NCT04606537 | Phase 1 | Oct 24, 2020 | Covance, KBP Biosciences |
| NCT04534699 | Phase 1 | Aug 27, 2020 | Covance, KBP Biosciences |
| NCT04575675 | Phase 4 | May 29, 2020 | Cheng-Hsin General Hospital |
| NCT03574363 | Phase 2 | Apr 25, 2018 | KBP Biosciences, Medpace, Inc. |
| NCT03340753 | Phase 1 | Oct 26, 2017 | KBP Biosciences, Medpace, Inc. |
| NCT02837237 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2016 | KBP Biosciences |
| NCT02653014 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2015 | KBP Biosciences |
| NCT02228733 | Phase 1 | Jun 1, 2014 | KBP Biosciences |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| KBP Biosciences | For profit | 9 | 9 | 3 | 2014 |
| Covance | For profit | 3 | 0 | 1 | 2020 |
| Medpace, Inc. | For profit | 2 | 0 | 2 | 2017 |
| Cheng-Hsin General Hospital | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of New South Wales | Academic/Hospital | 1 | 1 | 1 | 2024 |
5 organizations
Page 1 / 1